User contributions
(newest | oldest) View (newer 50 | older 50) (20 | 50 | 100 | 250 | 500)
- 21:23, 31 March 2020 (diff | hist) . . (+9) . . m Small cell lung cancer (current)
- 21:22, 31 March 2020 (diff | hist) . . (+76) . . m Durvalumab (Imfinzi) (current)
- 21:21, 31 March 2020 (diff | hist) . . (+182) . . m Durvalumab (Imfinzi) (→History of changes in FDA indication)
- 11:56, 31 March 2020 (diff | hist) . . (+211) . . m COVID-19 coronavirus and cancer (→Guidance for transplant)
- 17:55, 25 March 2020 (diff | hist) . . (+88) . . m COVID-19 coronavirus and cancer (→Potential treatments)
- 17:55, 25 March 2020 (diff | hist) . . (+25) . . m COVID-19 coronavirus and cancer (→Potential treatments)
- 17:50, 25 March 2020 (diff | hist) . . (+84) . . m COVID-19 coronavirus and cancer (→Potential treatments)
- 17:49, 25 March 2020 (diff | hist) . . (+17) . . m COVID-19 coronavirus and cancer (→Potential treatments)
- 19:42, 24 March 2020 (diff | hist) . . (+41) . . m COVID-19 coronavirus and cancer (→General information relevant to cancer patients)
- 19:41, 24 March 2020 (diff | hist) . . (+117) . . m COVID-19 coronavirus and cancer (→General information relevant to cancer patients)
- 13:26, 23 March 2020 (diff | hist) . . (+1,105) . . m COVID-19 coronavirus and cancer (→Guidance for transplant)
- 11:40, 23 March 2020 (diff | hist) . . (+181) . . m COVID-19 coronavirus and cancer (→Italy)
- 09:21, 22 March 2020 (diff | hist) . . (0) . . m COVID-19 coronavirus and cancer
- 13:23, 21 March 2020 (diff | hist) . . (+103) . . m COVID-19 coronavirus and cancer (→Oncology)
- 22:29, 20 March 2020 (diff | hist) . . (-73) . . m COVID-19 coronavirus and cancer (→COVID-19 and Cancer Consortium (CCC19))
- 22:33, 19 March 2020 (diff | hist) . . (+38) . . m COVID-19 coronavirus and cancer (→Potential treatments)
- 13:01, 19 March 2020 (diff | hist) . . (+12) . . m Multiple myeloma, relapsed-refractory (current)
- 12:38, 19 March 2020 (diff | hist) . . (+152) . . m Breast cancer, ER-positive (→Metastatic disease, subsequent lines of endocrine therapy) (current)
- 12:31, 19 March 2020 (diff | hist) . . (+146) . . m Breast cancer, ER-positive (→Metastatic disease, first-line endocrine therapy)
- 09:48, 19 March 2020 (diff | hist) . . (+63) . . m COVID-19 coronavirus and cancer (→COVID-19 and Cancer Consortium (CCC19))
- 09:42, 19 March 2020 (diff | hist) . . (+339) . . COVID-19 coronavirus and cancer (→COVID-19 and Cancer Consortium (CCC19))
- 21:20, 18 March 2020 (diff | hist) . . (-1) . . m COVID-19 coronavirus and cancer (→Oncology)
- 21:20, 18 March 2020 (diff | hist) . . (+68) . . m COVID-19 coronavirus and cancer (→Podcasts)
- 18:34, 17 March 2020 (diff | hist) . . (+1) . . m COVID-19 coronavirus and cancer (→COVID-19 and Cancer Consortium (CCC19))
- 18:34, 17 March 2020 (diff | hist) . . (-33) . . m COVID-19 coronavirus and cancer (→COVID-19 and Cancer Consortium (CCC19))
- 14:17, 17 March 2020 (diff | hist) . . (+792) . . m COVID-19 coronavirus and cancer
- 14:11, 17 March 2020 (diff | hist) . . (+37) . . m COVID-19 coronavirus and cancer
- 14:09, 17 March 2020 (diff | hist) . . (0) . . N File:Coronavirus-cdcc.jpg (current)
- 11:54, 17 March 2020 (diff | hist) . . (+1,268) . . Breast cancer, triple negative (→Cisplatin monotherapy {{#subobject:82336a|Regimen=1}}) (current)
- 11:51, 17 March 2020 (diff | hist) . . (-1) . . m TNBC (Redirected page to Breast cancer, triple negative) (current) (Tag: New redirect)
- 11:50, 17 March 2020 (diff | hist) . . (+45) . . N TNBC (Created page with "##REDIRECT Breast cancer, triple negative")
- 11:44, 17 March 2020 (diff | hist) . . (+1,220) . . m Hodgkin lymphoma (current)
- 11:36, 17 March 2020 (diff | hist) . . (+3,370) . . N CNS lymphoma - null regimens (Created page with "The purpose of this page is to provide references to "null therapy" such as placebo and observation. While not clinically relevant, these references provide further insight in...") (current)
- 11:36, 17 March 2020 (diff | hist) . . (-2,175) . . m CNS lymphoma (current)
- 11:22, 17 March 2020 (diff | hist) . . (+3) . . m Anaplastic glioma - null regimens (current)
- 10:11, 17 March 2020 (diff | hist) . . (+5,525) . . N Anaplastic glioma - null regimens (Created page with "The purpose of this page is to provide references to "null therapy" such as placebo and observation. While not clinically relevant, these references provide further insight in...")
- 09:55, 17 March 2020 (diff | hist) . . (-4,044) . . m Anaplastic glioma (current)
- 23:18, 16 March 2020 (diff | hist) . . (+1,122) . . m COVID-19 coronavirus and cancer (→Scientific Evidence on COVID-19 Occurrence in Cancer Patients)
- 23:11, 16 March 2020 (diff | hist) . . (+5,945) . . COVID-19 coronavirus and cancer (→Reports of medical center experiences)
- 22:27, 16 March 2020 (diff | hist) . . (+184) . . m COVID-19 coronavirus and cancer
- 22:25, 16 March 2020 (diff | hist) . . (+253) . . COVID-19 coronavirus and cancer
- 22:22, 16 March 2020 (diff | hist) . . (+528) . . COVID-19 coronavirus and cancer (→General information relevant to cancer patients)
- 20:26, 16 March 2020 (diff | hist) . . (+498) . . m COVID-19 coronavirus and cancer (→Guidance for transplant)
- 20:21, 16 March 2020 (diff | hist) . . (+409) . . m COVID-19 coronavirus and cancer (→Guidance for transplant)
- 20:21, 16 March 2020 (diff | hist) . . (+1) . . m ALL (Changed redirect target from Category:Acute lymphoblastic leukemia to Category:Acute lymphoblastic leukemias) (current) (Tag: Redirect target changed)
- 20:20, 16 March 2020 (diff | hist) . . (+52) . . N ALL (Redirected page to Category:Acute lymphoblastic leukemia) (Tag: New redirect)
- 20:20, 16 March 2020 (diff | hist) . . (+43) . . N DLBCL (Redirected page to Diffuse large B-cell lymphoma) (current) (Tag: New redirect)
- 20:17, 16 March 2020 (diff | hist) . . (+731) . . m COVID-19 coronavirus and cancer (→Guidance for transplant)
- 19:53, 16 March 2020 (diff | hist) . . (+201) . . m COVID-19 coronavirus and cancer (→General information relevant to cancer patients)
- 14:26, 16 March 2020 (diff | hist) . . (+6,495) . . N Acute promyelocytic leukemia - null regimens (Created page with "The purpose of this page is to provide references to "null therapy" such as placebo and observation. While not clinically relevant, these references provide further insight in...") (current)
(newest | oldest) View (newer 50 | older 50) (20 | 50 | 100 | 250 | 500)
